Clinical Trial

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective when given together with or without temozolomide in treating patients with low-grade glioma. PURPOSE: This randomized phase III trial is studying radiation therapy so see how well it works when given together with or without temozolomide in treating patients with low-grade glioma.
Protocol Amendment History 241 amendments
This ClinicalTrials.gov record has been amended 241 times since 2009-09-16; most recent amendment 2025-09-04.
Status change: Recruiting → Active, Not Recruiting 2017-12-12
Status change: Not Yet Recruiting → Recruiting 2009-10-29
Trial Details
NCT Number NCT00978458
Lead Sponsor Eastern Cooperative Oncology Group
Collaborators: National Cancer Institute (NCI)
Conditions Brain and Central Nervous System Tumors, Neurotoxicity
Enrollment 540 participants
Start Date 2009-11-17
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-08